Comparative effectiveness of combined antiplatelet treatments in acute minor ischaemic stroke.
Shina KimJoon Tae KimJi Sung LeeBeom Joon KimJong-Moo ParkKyusik KangSoo Joo LeeJae Guk KimJae-Kwan ChaDae-Hyun KimTai Hwan ParkSang-Soon ParkKyung Bok LeeJun LeeKeun-Sik HongYong-Jin ChoHong-Kyun ParkByung-Chul LeeKyung-Ho YuMi Sun OhDong-Eog KimWi-Sun RyuJay Chol ChoiJee-Hyun KwonWook-Joo KimDong-Ick ShinSung-Il SohnJeong-Ho HongMan-Seok ParkKang-Ho ChoiKi-Hyun ChoJuneyoung LeeHee-Joon BaePublished in: Stroke and vascular neurology (2021)
Other combined antiplatelet treatment, compared with aspirin alone or clopidogrel-aspirin, was not associated with reduced risks of primary composite vascular events or recurrent stroke during the first 3 months after stroke. Therefore, the results suggest that other combination treatments, particularly the cilostazol-based combination, may not be effective alternatives for clopidogrel-aspirin to prevent early vascular events in patients with acute minor stroke. Further exploration in clinical trials will be needed.
Keyphrases
- antiplatelet therapy
- low dose
- acute coronary syndrome
- percutaneous coronary intervention
- atrial fibrillation
- clinical trial
- cardiovascular events
- liver failure
- coronary artery disease
- anti inflammatory drugs
- respiratory failure
- drug induced
- cardiovascular disease
- risk assessment
- phase ii
- type diabetes
- combination therapy
- smoking cessation
- aortic dissection
- hepatitis b virus
- extracorporeal membrane oxygenation
- replacement therapy